Los Angeles Capital Management LLC Has $37.68 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Los Angeles Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11,433.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 137,017 shares of the biopharmaceutical company's stock after buying an additional 135,829 shares during the period. Los Angeles Capital Management LLC owned about 0.11% of Alnylam Pharmaceuticals worth $37,684,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ALNY. Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in Alnylam Pharmaceuticals by 47.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company's stock worth $415,000 after acquiring an additional 892 shares in the last quarter. Empowered Funds LLC boosted its position in Alnylam Pharmaceuticals by 3.9% during the 1st quarter. Empowered Funds LLC now owns 13,849 shares of the biopharmaceutical company's stock worth $2,070,000 after acquiring an additional 524 shares during the period. Headlands Technologies LLC purchased a new position in Alnylam Pharmaceuticals during the 1st quarter valued at about $471,000. Finally, ProShare Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 10.1% in the 1st quarter. ProShare Advisors LLC now owns 8,827 shares of the biopharmaceutical company's stock valued at $1,319,000 after purchasing an additional 809 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded up $2.39 during mid-day trading on Monday, hitting $279.82. 906,701 shares of the company were exchanged, compared to its average volume of 916,784. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business has a fifty day moving average of $274.52 and a 200 day moving average of $232.41. The company has a market capitalization of $36.09 billion, a PE ratio of -106.80 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts' expectations of $532.91 million. The firm's revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.15 earnings per share. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Royal Bank of Canada restated an "outperform" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a research note on Friday, November 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an "equal weight" rating in a research report on Friday, August 2nd. Finally, Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. Six equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $294.50.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the business's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares of the company's stock, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.